Clinical Evaluation of a New Single Pass Lead VDD Pacing System

Twenty-five patients with second- to third-degree AV block and normal sinus function (16 males, mean age 60 ± 18; range 15–78 years) underwent implantation of WD pacemakers (THERA VDD, Medtronic, Inc.) with a single pass (SP) lead. Results: During implantation the mean amplitude of the atrial (A) signal was 3.9 ±1.4 mV (range 2.0–7.8 mV). Stable, acceptable A-signals during implantation were usually observed in the mid- or lower part of the right atrium. The lead tip electrical parameters were not compro mised in any patient in order to obtain an acceptable A-signal. To verify VDD device function, patients underwent pacing system analysis on the second day and again 1, 3, and 6 months after implantation. Acute and chronic electrical measurements in the ventricle were similar to those with regular steroid leads. During follow-up tests, stable atrial sensing (A ≥ 0.7mV) was found in all but one patient (in whom A was 0.25–0.5 mV and an intermittent loss of atriai sensing occurred). There was no difference between serial measurements of A-signal amplitudes on the second day or 1, 3, and 6 months after implantation: 1.9 ± 1.3 mV, 1.5 ± 0.6 mV, 1.3 ± 0.8 mV, and 1.5 ± 1.1 mV, respectively. The mean implantation time was 54.0 ± 17 minutes and the mean fluoroscopy time was 3.2 ±1.3 minutes. Conclusions: SP lead VDD pacing is reliable and easy to manage with dependable atriai sensing and ventricular pacing. The significant reduction in atriai postimplantation amplitude is related to the different techniques used for measuring acute and chronic atriai signals.